The antifolate methotrexate (MTX) is one of the pillars of acute lymphoblastic leukemia (ALL) treatment. However, the efficacy of MTX is frequently hampered by drug resistance, which can contribute to relapse. Although a multitude of molecular mechanisms underlie drug resistance in model cell lines, their clinical relevance often remains elusive. The activity of folylpolyglutamate synthetase (FPGS) enzyme is essential for intracellular retention and cytotoxic activity of MTX. Hence, alterations in the FPGS gene are a plausible contributor to impaired FPGS activity in MTXresistant leukemia cells. Here we studied the association of FPGS splicing alterations with ex vivo MTX resistance as well as clinical response in 91 pediatric ALL patients. Our findings reveal that one FPGS splicing alteration -intron 8 partial retention (8 PR) exhibited a significant association with overall survival (HR=5.55, P=0.003) and event-free survival (HR=4.24, P=0.024) in a subset of patients displaying impaired accumulation of long-chain MTX polyglutamates. Moreover, high levels of intron 8 PR were indicative of resistance to several other chemotherapeutics including glucocorticoids, suggesting that the presence of intron 8 PR reflects a broader splicing defect resulting in multidrug resistance. These findings have important implications for personalized treatment and the circumvention of drug resistance in ALL patients.
INTROdUCTION
Advancements in patient-tailored chemotherapy and risk stratification along with good supportive care have greatly improved treatment outcome of pediatric acute lymphoblastic leukemia (ALL) resulting in 5-year event-free survival (EFS) of about 80%. 1 However, the risk of relapse in these patients reaches approximately 20%, and is associated with dismal prognosis. [1] [2] [3] Drug resistance remains a major cause of relapse and thereby continues to hinder current ALL therapies. Since its introduction in 1947, the antifolate methotrexate (MTX) has shown remarkable therapeutic efficacy and continues to be a key component of contemporary ALL treatment. 1, 4, 5 It is routinely used during the consolidation (iv HD-MTX) and maintenance (oral MTX) phase of ALL treatment, as well as in the prevention of central nervous system (CNS) involvement (HD-MTX and intrathecal MTX). 1, 6 As a folate antagonist, MTX blocks several folate-dependent enzymes, thereby impairing a number of crucial metabolic pathways including de novo biosynthesis of purines and thymidylate, amino acid conversion as well as mitochondrial protein synthesis. 7 This subsequently leads to inhibition of DNA replication resulting in cell death. 8 Under physiological conditions (i.e. pH 7.4), MTX is taken up into cells predominantly via the reduced folate carrier (RFC/SLC19A1) or upon HD-MTX treatment also by passive diffusion across the plasma membrane. [9] [10] [11] MTX cytotoxicity largely depends on the activity of folylpolyglutamate synthetase (FPGS), which catalyzes the stepwise addition of multiple glutamate residues (i.e. polyglutamylation) to both folates and antifolates. 10, 12 This unique metabolic conversion ensures higher intracellular retention of MTX as well as enhances target enzyme inhibition. [13] [14] [15] The main targets of polyglutamylated MTX include dihydrofolate reductase (DHFR; also inhibited by MTX monoglutamates), thymidylate synthase (TS) and several enzymes involved in purine biosynthesis. 10 The capacity of leukemic cells to accumulate high levels of MTX polyglutamates as determined in ex vivo ALL specimens was shown to be associated with an increased clinical efficacy of MTX and EFS of childhood ALL patients. 4, 16, 17 We have recently shown that the cellular levels of long-chain MTX polyglutamates are associated with favorable long term survival in childhood ALL patients treated with combination chemotherapy. 18 As such, impaired activity of FPGS in leukemic cells in vitro as well as in primary pediatric ALL specimens constitutes a well-established mechanism of resistance to polyglutamylation-dependent antifolates, including MTX. 12, 16, [19] [20] [21] [22] [23] [24] [25] [26] [27] Interestingly, impaired FPGSbased antifolate resistance in cell line models was the most prevalent upon intermittent exposure to high-dose polyglutamable antifolates including MTX -the clinically relevant mode of drug exposure. 28, 29 However, loss of FPGS activity after intermittent exposure to antifolates was often not paralleled by substantial decrease in FPGS mRNA levels, pointing to the involvement of a posttranscriptional mechanism.
20, 28, 30 In this respect, we reported that aberrant FPGS splicing constitutes a plausible basis for the loss of FPGS activity. [31] [32] [33] We revealed a range of FPGS mRNA splicing alterations in a panel of MTXand 7-OH-MTX-resistant human leukemia cell lines displaying low FPGS activity. 31, 33 These splicing aberrations were either absent from parental, MTX-sensitive cells, or were detected at lower levels.
Our bioinformatics modeling and in vitro ectopic overexpression combined with FPGS activity assay revealed that these splicing alterations are very likely to result in FPGS proteins devoid of catalytic activity. 33 Moreover, the ratio of the most prominent FPGS splicing alteration -intron 8 partial retention (intron 8 PR) to the wild type transcript markedly increased in response to treatment with antifolates 1 2 3 4 5 6 7 8
Aberrant FPGS splicing in clinical outcome of childhood ALL 9 & and other chemotherapeutic agents in antifolate-resistant cells, but not in their parental antifolate sensitive counterparts. 33 To date, the actual contribution of FPGS splicing alterations to MTX resistance in the clinical setting as well as their relevance to treatment outcome in ALL patients remains unclear. Therefore, the aim of the current study was to explore the relationship between impaired FPGS splicing and MTX resistance as well as the long term clinical outcome in childhood ALL patients.
MATERIALS ANd METhOdS

aLL patient specimens
This study included 91 newly diagnosed, untreated pediatric ALL patients treated either with the Dutch Childhood Oncology Group protocols (DCOG) ALL6 -ALL9 34, 35 or the German Co-operative ALL (COALL) protocols 92-97. 2, 36 The treatment details have been described elsewhere. 2, [34] [35] [36] The studies have been approved by the local medical ethical committees. All patients (or parents/legal guardians of patients) provided a written informed consent. Leukemic cell preparation, assessment of blast percentages, immunophenotyping and DNA index flow cytometry were performed as described previously. 18 Cryopreserved mononuclear (bone marrow or peripheral blood) cells of childhood ALL patients, including precursor B-cell and T-cell ALL at diagnosis were used in this analysis. RNA extraction and conversion to cDNA have been detailed in the Supplemental Materials and Methods.
FpGS splice variants
Screening for FPGS splicing alterations was performed using the previously described comprehensive polymerase chain reaction (PCR)-based assay, with 9 primer pairs (Supplemental Table S1 ). 33 PCR was carried out using 2x Reddy Mix PCR master mix (Thermo Fisher Scientific) and combined with fragment analysis (see Supplemental Materials and Methods). The ratios (percentages) of expression of particular FPGS splice variants over the wild type FPGS fragment were calculated based on the height of peaks corresponding to each PCR product.
In situ thymidylate Synthase inhibition assay (tSIa), MtX accumulation and polyglutamylation
Inhibition of TS and the assessment of the accumulation of MTX polyglutamates was determined in whole cells as described more in detail in Supplemental Materials and Methods. 25, 37, 38 The TSIA was used to measure in vitro efficacy of MTX to inhibit TS, which is known to reflect cytotoxicity in MTX exposed cells. Two conditions were used in the TSIA: a continuous 21 h incubation or a short 3 h exposure, followed by an 18 h drug-free period. The TSIA data are expressed as the concentration of MTX necessary to inhibit 50% of the TS activity (TSI 50 ) compared to the controls incubated without MTX (in triplicate). The MTX accumulation and polyglutamylation data are expressed as pmol MTXGlu n /10 9 cells.
FpGS activity assay
The FPGS activity assay was carried out in crude cell extracts upon a 2 h incubation with 
RESULTS
FpGS splicing alterations are associated with MtX resistance
The relation between FPGS splicing alterations and MTX resistance and treatment outcome was investigated in a cohort of 91 childhood ALL patients, for whom we have previously characterised a number of MTX-related parameters. 18 Since, not all variables characterising MTX sensitivity could be measured in all the patients in our cohort (due to limited number of leukemic blasts available as well as logistic reasons), the number of patients included in various analyses varied (and is listed in each Table/Figure) . To determine which splicing alterations occurring in FPGS mRNA are most likely associated with MTX resistance, we first performed a comprehensive PCR screen in a set of 34 pediatric ALL patient specimens, for which the most complete set of MTX resistance-related variables was available. The identity of the obtained PCR fragments was previously confirmed by sequencing to represent FPGS splice variants. 33 In total we successfully semi-quantified the levels of 11 different FPGS splicing alterations (Supplemental Table S2 ). For each FPGS splicing alteration detected, a ratio over the wild type exon-exon junctions in the amplified region was calculated (FPGS alternative variant/ FPGS WT variant, expressed as percentage). Subsequently, the obtained ratios were correlated to MTX resistance (TSIA - Table S3 ). Intriguingly, this cluster included all 3 alterations, which also correlated with the results of the short term TSIA. In addition, these FPGS splice variants also coincided with exon 5 skipping. Since intron 8 PR showed the strongest association with MTX resistance, this alteration together with variants correlating with intron 8 PR, as well as additional aberrations occurring in the same FPGS region (Supplemental Table S3 ), were further explored in a larger patient group (N=57), adding up to 91 patients in total. We have previously shown that MTX resistance differs substantially between precursor B-cell and T-cell leukemia samples. 18, 38 To assess if these differences are also reflected in FPGS splicing, we compared the levels of FPGS splice variants between these two subtypes of ALL (Table 2) . Interestingly, intron 8 PR, exon 6 skipping and intron 5 retention were found at higher levels in T-cell ALL (P=0.03, P=0.007 and P=0.04, respectively), while exon 5 skipping showed a trend to coincide with precursor B-cell ALL (P=0.08). When FPGS splicing alterations were correlated to MTX resistance-related variables, the associations were weaker than in the initial cohort (Supplemental Table S4 ). Intron 8 PR showed only a trend towards a positive association with the short term TSIA results in the total patient group, although it did not reach statistical significance (P=0.1). Intron 6 retention, as well as the other aberrations tested did not show any associations with ex vivo MTX resistance. Combined retention of intron 5 and 6 was significantly correlated with short term TSIA results in the total cohort, as well as in the precursor B-cell ALL (P=0.03 and P=0.021, respectively), although the correlation coefficients were rather low ( Table 2 ).
Intron 8 pr is associated with resistance to multiple chemotherapeutics
Since aberrant splicing of FPGS may possibly be the result of a broader splicing defect, we investigated whether or not FPGS splicing alterations are associated with resistance to other chemotherapeutics, as determined by an ex vivo cytotoxicity (MTT) assay. Intriguingly, this analysis revealed that intron 8 PR was strongly correlated with mitoxantrone (N=9, R=0.933, P<0.001) and dexamethasone resistance (N=14, R=0.650, P=0.01). A trend towards a positive association with resistance to doxorubicin was also observed, although it did not reach significance (N=13, R=0.500, P=0.08). The associations between intron 8 PR and both mitoxantrone (N=7, R=1, P<0.01) and dexamethasone (N=13, R=0.678, P=0.011) were also observed in precursor B-cell ALL. Unfortunately, the number of T-cell ALL patients for which these data were available was too low to allow analysis in this subgroup. Since the frequency distribution of intron 8 PR levels was bimodal, we have selected a cut-off value, which discriminated between the two subpopulations observed. Remarkably, high level of intron 8 PR was indicative of increased resistance to mitoxantrone, prednisone and dexamethasone (Table 3 ). These differences were present in the total patient cohort, as well as in precursor B-cell subtype of ALL (Supplemental Table S5 ). (Table 4 and  Supplemental Table S6 ). We have previously shown, that the level of long-chain MTX polyglutamates accumulated by the leukemic cells was associated with EFS and OS in pediatric ALL patients. 18 Since other mechanisms, such as high RFC activity or low expression of efflux pumps, can contribute to high levels of MTX polyglutamates accumulated in leukemic cells, we hypothesized that FPGS-dependent MTX resistance may be more relevant in patients with suboptimal accumulation of these active metabolites. Intriguingly, we found that the predictive value of the cellular levels of long-chain MTX polyglutamates is improved by combining it with the level of intron 8 PR ( Figure 1A ). In the subgroup of patients displaying lower levels of long-chain MTX polyglutamates, increased levels of intron 8 PR were indicative of inferior EFS and OS ( Figure 1A ). When this analysis was performed in precursor B-cell and T-cell ALL patients separately, the levels of intron 8 PR were significantly associated with survival in both subtypes of ALL ( Figure 1B and 1C) , although the numbers of cases were rather low. In multivariate analysis of OS and EFS, including WBC, lineage and age, high intron 8 PR levels were still significantly associated with worse outcome in this subgroup of patients which accumulated less of the long-chain MTX polyglutamates (Table 5 ). In addition, in this ALL subtype with inefficient polyglutamylation capacity, intron 8 PR was associated with higher TSI 50 values in the short-term MTX exposure (N=22, R=0.456, P=0.033), as well as with lower accumulation of long-chain MTX poyglutamates (N=38, R=-0.359, P=0.027, Supplemental Figure S1 ). When analyzed separately within the precursor B-cell or T-cell ALL subgroups, most of the associations became insignificant, possibly due to low sample numbers. The only correlation which remained significant in this analysis was the association between intron 8 PR levels and short-term TSIA in T-cell ALL (N=6, R=0.886, P=0.019). High MTX-Glu4-6, N=10
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Since several FPGS splicing alterations were detected in ALL patients, we further determined whether certain combinations of splice variants or the sum of ratios for all the observed alterations were better correlated with treatment outcome. The single relevant combination of FPGS splice variants was the concomitant intron 8 PR and exon 5 skipping and their combined effect was further evaluated in the entire patient cohort (Figure 2A and Table 4 ). Remarkably, we found that patients with high level of intron 8 PR together with low level of exon 5 skipping had inferior OS compared to the rest of patients (intron 8 PR low/exon 5 low or high; intron 8 PR high/exon 5 high). Similar trend was observed for EFS ( Figure 2A ). This parameter had an even stronger impact on OS in T-cell subtype of ALL ( Figure 2B ), although the sample number was very limited in this analysis. When analyzed in the total patient cohort, high level of intron 8 PR with simultaneous low levels of exon 5 skipping remained significantly associated with shorter OS in the multivariate analysis (Table 4 hazard ratio 3.21, P=0.02), taken into account known clinical factors (WBC, lineage and age). Similar trends were observed in the multivariate Cox regression analysis of EFS (Supplemental Table S7 ).
dISCUSSION
In this study, we demonstrate a wide variety of FPGS splicing alterations, most notably intron 8 PR, in a large cohort of pediatric ALL patients. We have previously shown that FPGS intron 8 PR leads to premature stop codon insertion and is predicted to result in an inactive FPGS devoid of the glutamate binding site -one of the important catalytic features of this enzyme. 33 Intron 8 PR was present in the majority of ALL specimens as well as in non-malignant samples, albeit at variable levels. 33 In the total ALL patient cohort we found no significant associations between single FPGS splicing aberrations and MTX resistance or the clinical outcome. However, considering the spectrum of mechanisms which contribute to MTX resistance in the clinical setting, it is conceivable that aberrant FPGS splicing is more important in certain subtypes of leukemia patients. In this respect, we have previously shown that low level of long-chain MTX polyglutamates is a strong predictor of unfavorable survival in pediatric ALL patients. 18 While leukemia patients with high accumulation of long-chain MTX polyglutamates all survive (Figure 1 ), we found that intron 8 PR expression level can further discriminate between favorable and inferior prognosis in patients with diminished levels of cellular MTX polyglutamates. Moreover, among patients with low accumulation of long-chain MTX polyglutamates intron 8 PR was an independent predictor of OS and EFS in multivariate Cox regression model corrected for WBC, lineage and age. In our study cohort herein, low levels of longchain MTX polyglutamates were significantly correlated with lower mRNA levels of RFC and FPGS as well as decreased FPGS activity (data not shown and 25, 41 ). This suggests that among patients with diminished FPGS function, individuals displaying high levels of intron 8 PR might have particularly low activity of this enzyme and consequently very poor response to MTX. Indeed, in the subgroup of patients accumulating low levels of MTX polyglutamates, intron 8 PR was associated with MTX resistance. The levels of several FPGS splicing alterations, including intron 8 PR, differed significantly between precursor B-cell and T-cell ALL, analogous to the inter-lineage differences in MTX response in leukemia. 25, 38, 41 T-cell ALL samples were previously shown to accumulate lower levels of MTX polyglutamates, which could partly be attributable to decreased FPGS mRNA expression and catalytic activity. 38, 41 It is therefore possible that higher levels of FPGS intron 8 PR found in the present study in precursor T-ALL, further contribute to decreased FPGS activity in this subtype of ALL. Interestingly, the association between the levels of intron 8 PR and clinical outcome in individuals characterized by low accumulation of long-chain MTX polyglutamates remained significant in both precursor B-cell and T-cell ALL. Since the treatment of ALL patients consists of a combination of different chemotherapeutics it is conceivable that this distinct splicing profile may also be associated with resistance to drugs other than antifolates. Indeed and intriguingly, FPGS intron 8 PR was also associated with resistance to other chemotherapeutics, some of which are routinely used in ALL treatment, including glucocorticoids and mitoxantrone. This correlation was observed in the total patient cohort as well as in precursor B-cell ALL, while the number of T-cell ALL samples was too low to allow this analysis. Glucocorticoid resistance is a known predictor of the outcome in pediatric ALL, however it was not possible to determine the relative attribution of this factor in our survival analysis, since data were incomplete for this parameter.
We have previously found that FPGS-deficient MTX-resistant human leukemia cells displaying high levels of intron 8 PR were surprisingly also highly resistant to dexamethasone (Supplemental Figure S2 and 33 ). These observations imply that intron 8 PR presumably reflects a broader splicing defect resulting in resistance to multiple chemotherapeutics, which most likely affects other genes as well. These genes have not yet been identified but could be either involved in drug metabolism or in regulation of apoptosis. In fact, expression of genes involved in glucocorticoid metabolism (i.e. glucocorticoid receptor -NR3C1) 42, 43 , as well as apoptosis [44] [45] [46] have previously been reported to be regulated by differential splicing. Therefore, the exact relation between intron 8 PR and clinical outcome, as well as intron 8 PR and glucocorticoid resistance should be further characterized in a larger cohort. Moreover, the potential underlying defect in splicing needs to be explored. This notion is underscored by the finding that ALL patients who displayed high level of intron 8 PR accompanied by a low level of exon 5 skipping had a worse EFS and OS, when compared to patients with all the other possible combinations of these two aberrations. This association was particularly strong in T-cell ALL. Our previous analysis of exon 5 skipping showed that this alteration results in premature translation termination, thereby leading to degradation of the transcript or truncated inactive protein. 33 These combined splicing alterations are probably a reflection of a general defect in splicing regulation in these cells. The underlying mechanisms are not yet unravelled but likely include alterations in certain splicing factors, which result in aberrant splicing profiles of various genes, ultimately leading to an inferior response to combination chemotherapy. However, this hypothesis requires further experimental exploration and validation. For accurate analysis of the contribution of each parameter of our comprehensive study to survival and drug resistance a large number of patient samples is required. The current study is rather limited in this respect despite an extensive cohort for which we have comprehensive data available. Moreover, this patient cohort is not fully representative of the typical treatment outcomes achieved in childhood ALL on these protocols, as the OS and EFS are lower than expected and relapses (and death after relapse) occur earlier than expected. This discrepancy is likely introduced by the selection of individuals for whom sufficient leukemic blasts were available for comprehensive analyses. Since, high blast count is a hallmark of more aggressive disease, the cohort used in the current study contains many patients with relatively poor outcome. For instance, when compared with DCOG protocol ALL8 or ALL9, in our cohort patients with high WBC or T-cell ALL were overrepresented (Supplemental Table S8 ) while gender and age at diagnosis were comparable. Taken altogether, our findings suggest that FPGS intron 8 PR as single splice variant as well as in combination with exon 5 skipping is related to MTX resistance and specific other drugs. Therefore specific splice variants and/or splice regulators are interesting potential prognostic markers for future patient stratification and personalized medicine in ALL. 
SUPPLEMENT MATERIALS ANd METhOdS
Isolation of rNa and cDNa synthesis
After thawing cryopreserved ALL patient samples, total RNA was extracted using AllPrep DNA/RNA/ Protein mini kit (Qiagen, Venlo, The Netherlands) and treated with DNaseI (Roche, Basel, Switzerland). One μg of the isolated RNA was converted to cDNA using Moloney Murine Leukemia Virus (M-MLV; Thermo Fisher Scientific, Waltham, USA) in a reaction buffer containing random hexamer primers (Roche), dNTPs (Roche), and a ribonuclease inhibitor Rnasin (Promega, Madison, USA).
Fragment analysis
In PCR combined with fragment analysis, the reverse primers were fluorescently labelled at their 5' end with 6-carboxyfluorescein. For semi-quantification the obtained PCR products were diluted in HiDi TM Formamide (Applied Biosystems, Foster City, USA) and subsequently resolved in capillary electrophoresis using the Genetic Analyzer 3500 system (Applied Biosystems). Data were analyzed using GeneMapper® Sofware v4.1 (Applied Biosystems).
ex vivo MtX sensitivity using in situ thymidylate Synthase inhibition assay 
MtX polyglutamylation
To assess the cellular levels of MTX poluglutamates, freshly isolated leukemic cells were incubated for 24 h with 1 μM [3', 5', 7-3 H]-MTX (Moravek Biochemicals; final specific activity 2 Ci/mmol). Subsequently, radioactivity, cell number and viability levels were assessed together with separation of the polyglutamates by high performance liquid chromatography using an anion exchange column as described previously. 18, 25, 40 
Statistical analysis
Associations between FPGS splicing alterations and variables related to drug resistance (including MTX) were analyzed using Spearman's Rho test. The Mann-Whitney U test was used to compare the variables related to MTX resistance as well as resistance to other chemotherapeutics, between ALL patients displaying high and low levels of particular FPGS splicing alterations. The cut-off values used to dichotomize variables were based on the frequency distribution among patients. In case of a bimodal distribution, the border was based on separating these two populations. For all other parameters we used median values as cut-off levels, while cut-offs for clinical factors were selected based on historical values. Kaplan-Meier analysis and Cox regression were used in the univariate analysis of EFS (defined as time from complete remission to an event) and OS in relation to the cellular levels of FPGS splice variants. Events included in EFS were relapse and death. MTX related variables, which showed significant impact on survival in the univariate analysis, were tested using the multivariate Cox regression model in the context of clinical factors with a known prognostic significance. 
